NCT03737994 2026-04-07
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT03596866 2025-09-12
ALTA-3
Takeda
Phase 3 Completed
NCT03535740 2025-07-31
ALTA-2
Takeda
Phase 2 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT03410108 2024-05-08
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 2 Completed
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT02706626 2023-01-26
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Criterium, Inc.
Phase 2 Terminated
NCT04634110 2022-10-24
Brigatinib Before Brain Irradiation Trial (B3i Trial)
University of Colorado, Denver
Phase 2 Terminated
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT01449461 2021-08-17
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Takeda
Phase 1/2 Completed
NCT02094573 2021-03-15
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Takeda
Phase 2 Completed